Endovascular Gene Delivery from a Stent Platform: Gene- Eluting StentsIlia Fishbein1,2*, Michael Chorny1,2, Richard F Adamo1, Scott P Forbes1, Ricardo A Corrales1, Ivan S Alferiev1,2 and Robert J Levy1,2
- *Corresponding Author:
- Ilia Fishbein
Department of Pediatrics
Division of Cardiology
The Children’s Hospital of Philadelphia, USA
Tel: (215) 590-8740
Fax: (215) 590-5454
E-mail: [email protected]
Received Date: June 27, 2013; Accepted Date: July 25, 2013; Published Date: July 27, 2013
Citation: Fishbein I, Chorny M, Adamo RF, Forbes SP, Corrales RA, et al. (2013) Endovascular Gene Delivery from a Stent Platform: Gene- Eluting Stents. Angiol 1:109. doi:10.4172/2329-9495.1000109
Copyright: © 2013 Fishbein I, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
A synergistic impact of research in the fields of post-angioplasty restenosis, drug-eluting stents and vascular gene therapy over the past 15 years has shaped the concept of gene-eluting stents. Gene-eluting stents hold promise of overcoming some biological and technical problems inherent to drug-eluting stent technology. As the field of gene-eluting stents matures it becomes evident that all three main design modules of a gene-eluting stent: a therapeutic transgene, a vector and a delivery system are equally important for accomplishing sustained inhibition of neointimal formation in arteries treated with gene delivery stents. This review summarizes prior work on stent-based gene delivery and discusses the main optimization strategies required to move the field of gene-eluting stents to clinical translation.